| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo 108-8639 [H. O., S. S., Y. F., T. K., S. H., Y. Nakaj., Y. Nakam.], and Department of Gastroenterological Surgery, Graduate School of Medicine, Kyoto University, Kyoto 606-8507 [H. O., S. S., T. K., Y. Y.], Japan
| ABSTRACT |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
Microarray technologies have enabled researchers to obtain comprehensive data about gene expression, not only in experimental models but also in human cancers (4 , 5) . In a previous report (6) , we compared expression profiles of 20 HCCs with their corresponding noncancerous liver tissues using a cDNA microarray consisting of 23,040 genes. Those experiments disclosed a number of genes that appeared to be involved in hepatocarcinogenesis and revealed moreover that expression profiles were different between hepatitis B virus-positive and hepatitis C virus-positive HCCs.
To identify ideal therapeutic targets, we chose to investigate genes that were commonly and exclusively up-regulated in HCCs, using data obtained from the microarray. In the work reported here, we isolated the entire transcript of a gene that was selectively expressed in cancerous tissues. This gene was eventually found to be identical to PEG10 (7) . Exogenous expression of PEG10 promoted growth of certain HCC cell lines that did not manifest endogenous expression of this gene. In addition, we demonstrated interaction of PEG10 protein with SIAH proteins, which play important roles in apoptosis. Our data raise novel insights into mechanisms of hepatocarcinogenesis and suggest that PEG10 might serve as a novel molecular target for treatment of HCCs.
| Materials and Methods |
|---|
|
|
|---|
RT-PCR.
RT-PCR experiments were carried out in 20-µl volumes of PCR buffer (TaKaRa, Tokyo, Japan), with 4 min at 94°C for denaturing followed by 20 (for GAPDH) or 30 (for PEG10 and SIAH1) cycles of 94°C for 30 s, 56°C for 30 s, and 72°C for 30 s in the GeneAmp PCR system 9700 (Perkin-Elmer, Foster City, CA). Primer sequences were as follows: for GAPDH, forward 5'-ACAACAGCCTCAAGATCATCAG-3' and reverse 5'-GGTCCACCACTGACACGTTG-3'; for PEG10, forward 5'-AACAACAACAACAACTCCAAGC-3' and reverse 5'-TCTGCACCTGGCTCTGCAG-3'; and for SIAH1, forward 5'-TCCAACAATGACTTGGCGAGT-3' and reverse 5'-CTTTTTCTGTGTGTGGCAGAG-3'.
Northern Blot Analysis.
Human multiple tissue blots (Clontech, Palo Alto, CA) were hybridized with a 32P-labeled PEG10 cDNA. Prehybridization, hybridization, and washing were performed according to the suppliers recommendations. The blots were autoradiographed with intensifying screens at -80°C for 24 h.
Immunoblotting.
The polyclonal antibody to PEG10 was purified from sera of immunized rabbits with recombinant GST-PEG10 protein produced in Escherichia coli. Cell extracts were prepared using lysis buffer [150 mM NaCl, 1% Triton X-100, 50 mM Tris-HCl (pH 7.4), and 1 mM DTT, with complete Protease Inhibitor Cocktail (Boehringer Mannheim, Mannheim, Germany). Proteins were separated by 10% SDS-PAGE and immunoblotted with the rabbit anti-PEG10 antibody. Horseradish peroxidase-conjugated goat antirabbit IgG (Santa Cruz Biotechnology, Santa Cruz, CA) served as the secondary antibody for the ECL Detection System (Amersham Pharmacia Biotech, Piscataway, NJ).
Immunohistochemical Staining.
Cultured cells on chamber slides were fixed with PBS containing 4% paraformaldehyde for 15 min, then rendered permeable with PBS containing 0.1% Triton X-100 for 2.5 min at room temperature. Frozen sections from primary HCCs and noncancerous liver tissue were fixed with acetone for 15 min. The cells were incubated with 2% BSA in PBS for 24 h at 4°C and hybridized with the anti-PEG10 antibody. Antibodies were stained with fluorescent substrate-conjugated antirabbit secondary antibody (ICN Pharmaceuticals, Costa Mesa, CA). Nuclei were counterstained with 4',6-diamidino-2-phenylindole. Fluorescent images were obtained with an Eclipse E800 microscope (Nikon, Tokyo, Japan).
Colony Formation Assay and Growth Suppression Assay.
Cells transfected with plasmid vector expressing the entire coding region of PEG10 using FuGENE6 reagent according to the suppliers protocol (Boehringer Mannheim) were cultured with an appropriate concentration of geneticin for 2 weeks, fixed with 100% methanol, and stained by Giemsa solution. Colonies > 1 mm were counted 2 weeks after transfection of pcDNA 3.1(+), pcDNA 3.1(-)/PEG10, or pcDNA 3.1(+)/PEG10. Cells transfected with sense (5'-CCTCGCGTGGTGAGTA-3') or antisense (5'-TACTCACCACGCGAGG-3') S-oligonucleotides of PEG10 were stained in the same manner.
Flow Cytometry.
A total of 1 x 105 cells was collected by trypsinization at the given time points and fixed in 70% cold ethanol. Cells treated with RNase and propidium iodide (50 µg/ml) in PBS were analyzed by a FACScan (Becton Dickinson, San Jose, CA).
Yeast Two-Hybrid Experiment.
A yeast two-hybrid assay was performed with the Matchmaker GAL4 Two-Hybrid System 3 according to the manufacturers protocols (Clontech). We cloned the entire coding sequence of PEG10 into the EcoRI-SalI site of pAS2-1 vector as bait and screened a human testis cDNA library (Clontech).
In Vitro Protein-binding Assay.
The entire coding regions of SIAH1 and SIAH2 were amplified using primers 5'-CGCGAATTCCGCCCACAGAAATGAGCC-3' and 5'-CATCTCGAGACATGGAAATAGTTACATTGATGC-3' or 5'-TGCGAATTCCATGGTTGGTTCGGAGC-3' and 5'-GTGCTCGAGGACAACATGTAGAAATAGTAAC-3', respectively, and cloned into appropriate cloning sites of pET21b vector (Novagen, Madison, WI) or pCMV-Flag5 (Sigma). Recombinant His-tagged SIAH-1 protein was prepared using the Xpress system (Invitrogen, Carlsbad, CA) according to the manufacturers recommendations. ProBond histidine affinity resin (Invitrogen) incubated with or without 10 µg of His-tagged SIAH-1 protein at 4°C for 1 h, followed by extensive washing with binding buffer [20 mM NaH2PO4, 500 mM NaCl (pH 7.8)], was then incubated with 50 µg of cell lysates from SNU423-PEG10 cells exogenously overexpressing PEG10 in NP40 lysis buffer [150 mM NaCl, 50 mM Tris (pH 8.0), and 1% NP40]. After the resin was washed with wash buffer (20 mM NaH2PO4 and 500 mM NaCl) twice each at pH 7.8, pH 6.0, and pH 5.5, protein was eluted with elution buffer (300 mM imidazole in wash buffer). The eluted proteins were analyzed by immunoblotting using anti-His probe antibody (Santa Cruz Biotechnology) or anti-PEG10 antibody. Similarly, GST or GST-PEG10 fusion protein, immobilized on Glutathione Sepharose 4B beads (Amersham Pharmacia Biotech, Uppsala, Sweden), was incubated with lysates from HEK293-SIAH2 cells overexpressing Flag-tagged SIAH2. Bound proteins were eluted with elution buffer [120 mM NaCl, 50 mM Tris-HCl (pH 8.0), and 20 mM glutathione (Sigma)] and analyzed by immunoblotting using anti-Flag (Sigma) and anti-PEG10 antibody.
Construction of Adenovirus Expressing SIAH1.
Generation and preparation of adenovirus-expressing SIAH1 was achieved using the Adenovirus Expression Vector Kit (TaKaRa) according to the suppliers protocol. First, the entire coding region of SIAH1 was amplified and cloned into an appropriate site of the pcDNA3.1/myc-C vector (Invitrogen). Subsequently, the fragment of myc-tagged SIAH1 was cloned into the cosmid vector pAxCAwt supplied in the kit. (TaKaRa).
| Results |
|---|
|
|
|---|
|
Promotion of Growth of Human Hepatoma Cells by PEG10.
To test the effects of PEG10 gene transfer on growth of hepatoma cells, we transfected an expression plasmid containing PEG10 to two cell lines (SNU423 and SNU475), which had shown no endogenous expression of PEG10 protein (Fig. 1B)
. Compared with mock or antisense plasmid clones, the PEG10 sense plasmid vector promoted colony formation in both cell lines (Fig. 2A)
. To additionally investigate the growth-promoting effects of PEG10, we generated stable transfectants using SNU423 cells in which endogenous PEG10 expression was absent (Fig. 2B)
. The PEG10 stable transfectant cells revealed significant growth promotion compared with the parental or mock cells (Fig. 2C)
. Under conditions of serum starvation (0.1% FBS), the mock cells rapidly underwent growth arrest, but stable PEG10-expressing cells continued to proliferate (Fig. 2D)
.
|
Interaction of PEG10 with SIAH-1 and SIAH-2.
To examine the oncogenic mechanism of PEG10, we searched for PEG10-interacting proteins using a yeast two-hybrid screening system because the NH2-terminal region of PEG10 also contains a coiled-coil motif that generally allows for protein-protein interactions. Among the clones identified, those homologous to Drosophila seven in absentia (SIAH1 and SIAH2) interacted with PEG10 by simultaneous transformation with pAS2.1-PEG10 and pACT2-SIAH1 or SIAH2 (Fig. 3A)
. To confirm the interaction of PEG10 with SIAH1, we prepared recombinant His-tagged SIAH1 protein and detected this association when PEG10 protein was expressed in mammalian cells (Fig. 3B)
. In addition, we demonstrated association of GST-PEG10 fusion protein with flag-tagged SIAH2 protein expressed in HEK293 cells (Fig. 3C)
.
|
|
| Discussion |
|---|
|
|
|---|
Transfer of PEG10 into hepatoma cells that expressed no detectable endogenous PEG10 protein elicited significant growth promotion activity. Serum starvation did not suppress the growth of cells that expressed PEG10 at high levels. Because transfer of PEG10 into HEK293, Cos7, and NIH3T3 cells did not promote growth (data not shown), our data indicate that the oncogenic activity of PEG10 is likely to be specific to hepatocytes.
PEG10 shows 61.4% homology to murine myelin expression factor 3, the product of which is thought to function as a transcriptional factor and to control expression of myelin basic protein during brain development (12) . Myelin expression factor 3 protein consists of 235 amino acids with a zinc finger domain in the COOH-terminal region. Conservation of this domain may indicate that PEG10 itself functions as a transcriptional factor.
We found that PEG10 protein was able to interact with SIAH1 and SIAH2 proteins, which are homologues of Drosophila seven in absentia (sina); the latter is involved in the fate of R7 photoreceptor cells of Drosophila during eye development (13) . SIAH1 protein is involved in ubiquitin-mediated proteolysis of several proteins, including kinesin-like DNA binding protein, BAG-1, and DCC (deleted in colorectal cancer) via its RING finger domain (14, 15, 16) . This gene is located on chromosomal band 16q12-q13, a region frequently deleted in tumors arising from various tissues, including HCCs (17 , 18) , suggesting that SIAH1 might function as a tumor suppressor. Furthermore, SIAH1 was shown to interact with the tumor suppressor adenomatous polyposis coli and facilitates degradation of ß-catenin through formation of a degradation complex that is independent of glycogen synthase kinase-3ß (19 , 20) . Notably, we observed a marked decrease of PEG10 protein by exogenous expression of SIAH1 in Huh7 and HepG2 cells (data not shown), suggesting that SIAH1 may exert its tumor-suppressive function by degrading oncogeneic proteins, including BAG-1, ß-catenin, and PEG10. Although we carried out immunoprecipitation assays using overexpression of PEG10 together with SIAH1, we were unable to detect their association, indicating that SIAH1-associated PEG10 might be quickly degraded through ubiquitin-proteosome pathway. The reduced expression of SIAH1 in HCC cell lines and induction of apoptosis after transfer of exogenous SIAH1 into HCC cells suggest that SIAH1 plays an important role in suppressing hepatocarcinogenesis.
In our experiments, cells that stably expressed PEG10 revealed a significant decrease in cell death in response to Ad-SIAH1, suggesting that imbalance between expression of PEG10 and SIAH1 may be involved in hepatocarcinogenesis through inhibition of apoptosis. PEG10 was isolated as a paternally expressed gene from a newly defined imprinted region at 7q21 (7) . Loss of imprinting might be involved in the elevated expression of this gene in HCCs, although we found no evidence to support it. Hence, the actual mechanisms by which the expression of PEG10 is deregulated in HCCs remain to be investigated.
Finally, we have demonstrated that reduction of PEG10 expression by treatment with antisense S-oligonucleotides decreases growth of HCC cells significantly. Interestingly, the antisense sequences suppressed growth only of HCC cells that endogenously expressed PEG10, not in cell lines that did not. Because expression of this gene was enhanced in the majority of HCC tissues and very low or absent among all normal adult human tissues, except gonadal glands, suppression of PEG10 might be an ideal therapeutic strategy for treating primary HCCs. Although additional functional analysis of PEG10 is required, the data provided here should contribute to a more profound understanding of hepatocarcinogenesis and to development of novel therapeutic approaches.
| FOOTNOTES |
|---|
1 This work was supported by "Research for the Future" Program Grant 00L01402 from the Japan Society for the Promotion of Science. ![]()
2 To whom requests for reprints should be addressed, at Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan. Phone: 81-3-5449-5372; Fax: 81-3-5449-5433; E-mail: yusuke{at}ims.u-tokyo.ac.jp ![]()
3 The abbreviations used are: HCC, hepatocellular carcinoma; HEK293, human embryonic kidney 293; PEG10, the paternally expressed gene 10; GST, glutathione S-transferase; RT-PCR, reverse transcription-PCR; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; MOI, multiplicity of infection; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide. ![]()
4 Internet address: http://smart.embl-heidelberg.de. ![]()
Received 9/ 3/02. Accepted 5/ 1/03.
| REFERENCES |
|---|
|
|
|---|
-tubulin and degrades the kinesin Kid by the proteasome pathway during mitosis. Oncogene, 19: 5997-6006, 2000.[Medline]
This article has been cited by other articles:
![]() |
K. Nakayama, J. Qi, and Z. Ronai The Ubiquitin Ligase Siah2 and the Hypoxia Response Mol. Cancer Res., April 1, 2009; 7(4): 443 - 451. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. B. Clark, M. Janicke, U. Gottesbuhren, T. Kleffmann, M. Legge, E. S. Poole, and W. P. Tate Mammalian Gene PEG10 Expresses Two Reading Frames by High Efficiency 1 Frameshifting in Embryonic-associated Tissues J. Biol. Chem., December 28, 2007; 282(52): 37359 - 37369. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Wang, H. Yuling, J. Yanping, T. Xinti, Y. Yaofang, Y. Feng, X. Ruijin, W. Li, C. Lang, L. Jingyi, et al. CCL19 and CXCL13 Synergistically Regulate Interaction between B Cell Acute Lymphocytic Leukemia CD23+CD5+ B Cells and CD8+ T Cells J. Immunol., September 1, 2007; 179(5): 2880 - 2888. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. W. Zhang, H. C. Cheng, C. D. Jiang, C. Y. Deng, Y. Z. Xiong, F. E. Li, and M. G. Lei Imprinted status of pleomorphic adenoma gene-like I and paternal expression gene 10 genes in pigs J Anim Sci, April 1, 2007; 85(4): 886 - 890. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Chunsong, H. Yuling, W. Li, X. Jie, Z. Gang, Z. Qiuping, G. Qingping, Z. Kejian, Q. Li, A. E. Chang, et al. CXC Chemokine Ligand 13 and CC Chemokine Ligand 19 Cooperatively Render Resistance to Apoptosis in B Cell Lineage Acute and Chronic Lymphocytic Leukemia CD23+CD5+ B Cells J. Immunol., November 15, 2006; 177(10): 6713 - 6722. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Dekel, S. Metsuyanim, K. M. Schmidt-Ott, E. Fridman, J. Jacob-Hirsch, A. Simon, J. Pinthus, Y. Mor, J. Barasch, N. Amariglio, et al. Multiple Imprinted and Stemness Genes Provide a Link between Normal and Tumor Progenitor Cells of the Developing Human Kidney. Cancer Res., June 15, 2006; 66(12): 6040 - 6049. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-M. Li, A. A. Margolin, M. Salas, L. Memeo, M. Mansukhani, H. Hibshoosh, M. Szabolcs, A. Klinakis, and B. Tycko PEG10 Is a c-MYC Target Gene in Cancer Cells Cancer Res., January 15, 2006; 66(2): 665 - 672. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Santelli, M. Leone, C. Li, T. Fukushima, N. E. Preece, A. J. Olson, K. R. Ely, J. C. Reed, M. Pellecchia, R. C. Liddington, et al. Structural Analysis of Siah1-Siah-interacting Protein Interactions and Insights into the Assembly of an E3 Ligase Multiprotein Complex J. Biol. Chem., October 7, 2005; 280(40): 34278 - 34287. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Manktelow, K. Shigemoto, and I. Brierley Characterization of the frameshift signal of Edr, a mammalian example of programmed -1 ribosomal frameshifting Nucleic Acids Res., March 14, 2005; 33(5): 1553 - 1563. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Lux, C. Beil, M. Majety, S. Barron, C. J. Gallione, H.-M. Kuhn, J. N. Berg, P. Kioschis, D. A. Marchuk, and M. Hafner Human Retroviral gag- and gag-pol-like Proteins Interact with the Transforming Growth Factor-{beta} Receptor Activin Receptor-like Kinase 1 J. Biol. Chem., March 4, 2005; 280(9): 8482 - 8493. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Chevillard, N. Ugolin, P. Vielh, K. Ory, C. Levalois, D. Elliott, G. L. Clayman, and A. K. El-Naggar Gene Expression Profiling of Differentiated Thyroid Neoplasms: Diagnostic and Clinical Implications Clin. Cancer Res., October 1, 2004; 10(19): 6586 - 6597. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |